このエントリーをはてなブックマークに追加
ID 53675
JaLCDOI
フルテキストURL
著者
Sugiu, Kumi Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Iwamoto, Takayuki Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Kelly, Catherine M. Department of Oncology, Mater Misericordiae University Hospital
Watanabe, Naoki Department of Surgery, Chugoku Central Hospital
Motoki, Takayuki Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Itoh, Mitsuya Department of Breast Surgery, Hiroshima City Hospital
Ohtani, Shoichiro Department of Breast Surgery, Hiroshima City Hospita
Higaki, Kenji Department of Breast Surgery, Hiroshima City Hospital
Imada, Takako Department of Surgery, Okayama Central Hospital
Yuasa, Takeshi Department of Surgery, Himeji Red Cross Hospital
Omori, Masako Department of Pathology, Okayama University Hospital
Sonobe, Hiroshi Department of Pathology, Chugoku Central Hospital
Fujiwara, Toshiyoshi Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science
Matsuoka, Junji Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science b Department of Breast and Endocrine Surgery, Okayama University Hospital
抄録
Although in the neoadjuvant setting for estrogen receptor (ER)-positive breast cancers, chemotherapy or hormone therapy alone does not result in satisfactory tumor response, it is unknown whether concurrent chemo-endocrine therapy is superior to chemotherapy alone in clinical outcomes. We conducted a randomized phase II trial to test the responses of ER-positive patients to concurrent administration of chemo-endocrine therapy in the neoadjuvant setting. Women with stage II-III, ER-positive, invasive breast cancer (n=28) received paclitaxel followed by fluorouracil, epirubicin, cyclophosphamide (T-FEC) and were randomized to receive concurrent chemo-endocrine therapy consisting of goserelin administered subcutaneously for premenopausal women or an aromatase inhibitor for postmenopausal women. The primary endpoint was the pathological complete response (pCR) rate after neoadjuvant therapy. Twenty-eight patients were randomized. There were no significant differences in pCR rate between the concurrent group (12.5%;2/16) and the chemotherapy alone group (8.3%;1/12). Tumor size after therapy was significantly reduced in the concurrent therapy group (p=0.035), but not in the chemotherapy-alone group (p=0.622). Neoadjuvant chemotherapy with concurrent hormone therapy provided no significant improvement in pCR rate in ER-positive breast cancers. These preliminary results should be followed up by further studies.
キーワード
breast cancer
neoadjuvant chemotherapy
concurrent hormone therapy
estrogen receptor positive
tumor response
Amo Type
Original Article
発行日
2015-10
出版物タイトル
Acta Medica Okayama
69巻
5号
出版者
Okayama University Medical School
開始ページ
291
終了ページ
299
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2015 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT